Chapter title |
Diagnosis and Treatment of IgG4-Related Disease
|
---|---|
Chapter number | 36 |
Book title |
IgG4-Related Disease
|
Published in |
Current topics in microbiology and immunology, January 2016
|
DOI | 10.1007/82_2016_36 |
Pubmed ID | |
Book ISBNs |
978-3-31-952541-9, 978-3-31-952542-6
|
Authors |
Terumi Kamisawa, Kazuichi Okazaki, Kamisawa, Terumi, Okazaki, Kazuichi |
Abstract |
It is critical to differentiate IgG4-related disease (IgG4-RD) from malignant tumor and similar disease of the affected organ to apply appropriate therapy and avoid unnecessary surgery. IgG4-RD is diagnosed on combination of typical radiological findings; elevation of serum IgG4 levels; histopathological findings of abundant infiltration of IgG4-positive plasma cells and lymphocytes, storiform fibrosis , and obliterative phlebitis ; association with other IgG4-related diseases; and response to steroids. Histopathological approach is particularly recommended. Systemic glucocorticoids are currently the first-line approach for IgG4-RD, and the indications are symptoms. The initial recommended dose of oral prednisolone for induction of remission is 0.6 mg/kg/day, administered for 2-4 weeks. This dose is gradually tapered to a maintenance dose of 2.5-5 mg/day over a period of 2-3 months. As IgG4-RD sometimes relapses after steroids, maintenance therapy is usually performed in Japan. However, as IgG4-RD patients are typically elderly and are at high risk of developing steroid-related complications, cessation of the medication should be attempted at least within 3 years. For relapsed IgG4-RD, re-administration or dose up of steroid is effective, but the addition of immunomodulatory drugs such as azathioprine has been considered to be appropriate. B cell depletion with rituximab (an anti-CD20 antibody) is effective, even in many patients in whom treatment with immunomodulatory drugs was unsuccessful. The short-term clinical, morphological, and functional outcomes of most IgG4-RD patients treated with steroid therapy are good, but the long-term outcomes are less clear due to several unknown factors such as relapse, developed fibrosis, and associated malignancy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Ecuador | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 62 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 11 | 18% |
Student > Bachelor | 9 | 15% |
Researcher | 7 | 11% |
Student > Ph. D. Student | 4 | 6% |
Student > Postgraduate | 4 | 6% |
Other | 12 | 19% |
Unknown | 15 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 44% |
Immunology and Microbiology | 7 | 11% |
Nursing and Health Professions | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Other | 2 | 3% |
Unknown | 20 | 32% |